Literature DB >> 3166905

Inhibition of mitogen stimulated growth of human colon cancer cells by interferon.

A W Hamburger1, M E Condon, K O'Donnell.   

Abstract

Recombinant human interferon alpha inhibits growth of a human colon cancer cell line, Colo 205. To explore the mechanisms of IFN induced growth inhibition, quiescent Colo 205 cells were stimulated to proliferate in serum-free media by defined growth factors. Addition of insulin, transferrin and selenium (ITS) stimulated DNA synthesis, as measured by 3H-thymidine incorporation, in a dose-dependent manner. IFN-alpha (at concentrations greater than 100 U ml-1) inhibited ITS stimulated DNA synthesis by 63%. Inhibition of cell cycle traverse was confirmed by flow cytometric analysis. Although IFN inhibited growth of ITS-treated cells, steady state levels of c-myc mRNA remained above levels observed in unstimulated cells. IFN inhibited DNA synthesis only when added prior to mitogen stimulation. IFN, added 6 h after exposure of quiescent cells to ITS, failed to inhibit cell growth. Addition of increasing concentrations of ITS failed to overcome the IFN-induced growth inhibition. These results suggest IFN may inhibit cell growth in part by antagonizing the action of growth factors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3166905      PMCID: PMC2246752          DOI: 10.1038/bjc.1988.182

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  22 in total

1.  Effect of human recombinant alpha-2- and gamma-interferon on the growth of human cell lines from solid tumors and hematologic malignancies.

Authors:  H Denz; M Lechleitner; C Marth; G Daxenbichler; G Gastl; H Braunsteiner
Journal:  J Interferon Res       Date:  1985

2.  The effects of interferon on epidermal growth factor action.

Authors:  S L Lin; P O Ts'o; M D Hollenberg
Journal:  Biochem Biophys Res Commun       Date:  1980-09-16       Impact factor: 3.575

3.  beta-Interferon alters the pattern of proteins secreted from quiescent and platelet-derived growth factor-treated BALB/c-3T3 cells.

Authors:  S Tominaga; P Lengyel
Journal:  J Biol Chem       Date:  1985-02-25       Impact factor: 5.157

4.  Inhibitory effect of interferon on cellular DNA synthesis: modulation by pure mitogenic factors.

Authors:  J Taylor-Papadimitriou; M Shearer; E Rozengurt
Journal:  J Interferon Res       Date:  1981

5.  Platelet-derived growth factor (PDGF) inhibits antiviral and anticellular actin of interferon in synchronized mouse or human cells.

Authors:  E Oleszak; A D Inglot
Journal:  J Interferon Res       Date:  1980

6.  Differential effects of epidermal growth factor, transforming growth factor, and insulin on DNA and protein synthesis and morphology in serum-free cultures of AKR-2B cells.

Authors:  G D Shipley; C B Childs; M E Volkenant; H L Moses
Journal:  Cancer Res       Date:  1984-02       Impact factor: 12.701

7.  Close link between reduction of c-myc expression by interferon and, G0/G1 arrest.

Authors:  M Einat; D Resnitzky; A Kimchi
Journal:  Nature       Date:  1985 Feb 14-20       Impact factor: 49.962

8.  Translocation and rearrangements of the c-myc oncogene locus in human undifferentiated B-cell lymphomas.

Authors:  R Dalla-Favera; S Martinotti; R C Gallo; J Erikson; C M Croce
Journal:  Science       Date:  1983-02-25       Impact factor: 47.728

9.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

10.  Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining.

Authors:  A Krishan
Journal:  J Cell Biol       Date:  1975-07       Impact factor: 10.539

View more
  1 in total

1.  Posttranscriptional regulation of c-myc proto-oncogene expression and growth inhibition by recombinant human interferon-beta ser17 in a human colon carcinoma cell line.

Authors:  D Chatterjee; T M Savarese
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.